Oncology Company Achieves ~80% Acceleration in Gene Target ID/ Validation
Key Highlights
An early-stage US-based pharmaceutical company was studying the effect of gene perturbation on cell fate conversion to develop a novel treatment method for widespread health disorders.
Elucidata completed the custom curation process of 50+ datasets in a brief period of 2 months and identified 2 targets that could regulate cell fate reprogramming.
Our established curation infrastructure and data processing pipelines increased the overall speed of analysis which helped them identify and validate the targets in 5-6 months instead of the typical time-period of more than a couple of years!
Oncology Company Achieves ~80% Acceleration in Gene Target ID/ Validation
Key Highlights
An early-stage US-based pharmaceutical company was studying the effect of gene perturbation on cell fate conversion to develop a novel treatment method for widespread health disorders.
Elucidata completed the custom curation process of 50+ datasets in a brief period of 2 months and identified 2 targets that could regulate cell fate reprogramming.
Our established curation infrastructure and data processing pipelines increased the overall speed of analysis which helped them identify and validate the targets in 5-6 months instead of the typical time-period of more than a couple of years!
%20(1).svg)
%201%20(1).svg)
%20(1).svg)
%201%20(1).svg)
.svg)
.webp){kind=spacer}
.webp)
.webp)
.webp)
.webp)
.png)
.webp)
.webp)
.webp)
